The Motley Fool Discussion Boards

Previous Page



Subject:  Re: Aphria & Canopy's Sweetheart Tetra Bio-P Date:  10/24/2019  9:50 AM
Author:  MightyMaven Number:  255 of 430

This was posted on Reddit a couple of months back, and is a quote from Carl Merton, the CFO of Aphria, about Tetra Bio-Pharma. He discusses the share price and soundness of Tetra bio-Pharma, so it is appropriate to add it here:

"Not sure what you are looking for in this answer. I presume it is the share price. I will willingly admit; I have no idea what is going on with TBP’s share price. Its current level defies logic. The business is extremely sound. The studies it is involved with continue to progress forward. They had a backwards step with TBP001, that was driven more by Health Canada’s lack of rules on an issue than an actual issue (as evidence by the trial moving forward with the EMA).

I think in the early days of TBP’s communication with investors, the communications was driven too often by science and not enough by investor relations. (As an investment writer, I agree wholeheartedly!) It can be very difficult to take the complex clinical situations and explain them properly to investors. In the last year, we spent a great deal of effort modifying the MD&A and press releases to be more investor driven (written for them) than the science / clinical side of things. I think the documents are much better and commend the team at TBP for the changes. I hope investors feel the same way." (Note he brings up the importance of reading their MD&A, one of the three filings I urged readers to locate and read. MD&A, AIF and short form prospecus. They contain a lot of news information that could have been PR'd in news releases, in my opinion. Certainly it's necessary knowledge to have.)
Copyright 1996-2020 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us